Medical Market Report

Global Imatinib Drug Market By Type (Tablets, and Capsules), By Application (Chronic myelogenous leukemia, Gastrointestinal stromal tumors, and Others), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 139041
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Imatinib Drug Market is estimated to be valued US$ XX.X million in 2019. The report on Imatinib Drug Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global imatinib drug market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Imatinib Drug Market Scope:

    By type, the market is segmented into Tablets, and Capsules. By Application, the market is divided into Chronic myelogenous leukemia, Gastrointestinal stromal tumors, and Others.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Novartis, Glenmark Pharmaceuticals, Sun Pharmaceuticals, Actavis Generics, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, Sanofi S.A., Cipla, Apotex, and Mylan Pharms.

    Key Market Segments

    Type

    Tablets

    Capsules

    Application

    Chronic myelogenous leukemia

    Gastrointestinal stromal tumors

    Others

    Key Market Players included in the report:

    Novartis

    Glenmark Pharmaceuticals

    Sun Pharmaceuticals

    Actavis Generics

    Dr. Reddy’s Laboratories

    Teva Pharmaceutical Industries

    Sanofi S.A.

    Cipla

    Apotex

    Mylan Pharms

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Imatinib Drug Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Imatinib Drug Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Imatinib Drug Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Imatinib Drug Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Imatinib Drug Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Imatinib Drug Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Imatinib Drug sub-markets, depending on key regions (various vital states).
    To analyze Imatinib Drug Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Imatinib Drug Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Imatinib Drug Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Imatinib Drug Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Imatinib Drug Market Overview
    

    3.1. Imatinib Drug Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Imatinib Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Imatinib Drug Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Tablets
    

      4.4. Capsules
    

    5. Global Imatinib Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Imatinib Drug Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Chronic myelogenous leukemia
    

      5.4. Gastrointestinal stromal tumors
    

      5.5. Others
    

    6. Global Imatinib Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Imatinib Drug Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Imatinib Drug Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Imatinib Drug Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Imatinib Drug Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Imatinib Drug Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Imatinib Drug Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Novartis
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Glenmark Pharmaceuticals
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Sun Pharmaceuticals
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Actavis Generics
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Dr. Reddy’s Laboratories
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. Teva Pharmaceutical Industries
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Sanofi S.A.
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Cipla
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Apotex
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. Mylan Pharms
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.